leucine rich repeat containing 37 member A5, pseudogeneGenealiases: []
Q-omics provides the consensus-scored LRRC37A5P profile across patient tissues and cancer cell-line models. LRRC37A5P expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, LRRC37A5P is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, LRRC37A5P RNA expression shows 13,076 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, KICH, and TGCT as cancer lineages where LRRC37A5P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC37A5P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC37A5P survival associations across molecular data types. LRRC37A5P RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC37A5P RNA expression–survival associations across cancer types. High LRRC37A5P expression shows unfavorable associations in UCS, COAD and BLCA, but favorable associations in UVM, MESO and UCEC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for LRRC37A5P RNA expression.
This table summarizes LRRC37A5P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC37A5P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC37A5P shows lower tumor expression in KICH, KIRC, THCA, LUSC, LUAD and UCEC. The KICH box plot shows higher LRRC37A5P RNA expression in normal versus tumor tissue (log2 FC = −1.726, t-test p < 0.001).
This table shows molecular features associated with LRRC37A5P in patient tissues and cancer cell lines. In patient samples, LRRC37A5P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC37A5P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE.
